Difamilast vs Crisaborole: Topical PDE4 Inhibitors for Atopic Dermatitis in Pediatrics and Adults

Executive Brief

News Report

The News: Difamilast and crisaborole are key treatments for atopic dermatitis.
Clinical Win: Both drugs offer effective management options for pediatric and adult patients.
Target Specialty: Dermatology

Key Data at a Glance

Crisaborole Approval: Approved for patients aged 2 and older.
Difamilast Indication: Indicated for atopic dermatitis.

The comparison of difamilast and crisaborole as topical phosphodiesterase 4 (PDE4) inhibitors for atopic dermatitis management has emerged as a significant topic for clinicians, particularly with new guidelines expected in 2026. This comparison is crucial as both treatments offer options for managing atopic dermatitis in pediatric and adult populations, addressing a common and often challenging condition.

Clinical Context

Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by pruritus, erythema, and xerosis, affecting both children and adults. The condition can significantly impact quality of life, leading to sleep disturbances, anxiety, and social stigma. Current treatment options include topical corticosteroids, calcineurin inhibitors, and more recently, PDE4 inhibitors like crisaborole (Eucrisa) and difamilast (Adquey). Crisaborole was approved by the FDA in 2016 for use in patients aged two years and older, demonstrating efficacy in reducing the severity of atopic dermatitis. Difamilast, a newer entrant, is also indicated for the treatment of AD and is being evaluated for its comparative effectiveness against crisaborole. The emergence of these options highlights the need for clinicians to understand the nuances in their use, particularly in pediatric populations where safety and tolerability are paramount.

Key Findings

The FDA has approved crisaborole (Eucrisa) for the treatment of atopic dermatitis in patients aged two years and older, showing a reduction in the severity of the condition compared to vehicle control in clinical trials [1].

Difamilast (Adquey) is also indicated for atopic dermatitis and is currently under review for its comparative efficacy against crisaborole, with studies suggesting similar effectiveness in reducing AD symptoms [2].

Both treatments are applied topically, with difamilast typically administered twice daily, while crisaborole is applied as needed, providing flexibility in management strategies for patients and caregivers.
Clinicians should consult current prescribing information for full dosing guidance.

The primary endpoint in trials for both medications has been the improvement in the Eczema Area and Severity Index (EASI) score, a widely recognized measure of disease severity [1][2].

What This Means for Clinical Practice

The comparison between difamilast and crisaborole is vital for clinicians managing atopic dermatitis, particularly in pediatric patients. Understanding the differences in application frequency, safety profiles, and efficacy can guide treatment decisions tailored to individual patient needs. As difamilast continues to be evaluated, clinicians should remain informed about emerging data and guidelines to optimize care for patients with atopic dermatitis. The choice between these two PDE4 inhibitors may ultimately depend on patient-specific factors, including age, severity of disease, and response to previous treatments. How these findings will influence clinical practice and guideline recommendations in 2026 remains to be seen.

Clinical Perspective

Workflow: Clinicians should incorporate these topical treatments into their management plans for atopic dermatitis.

Economics: Understanding the cost-effectiveness of these treatments can aid in resource allocation.

Patient Outcomes: Improved symptom management can enhance quality of life for patients with atopic dermatitis.

Dr. Divya Agarwal, Dermatology

Difamilast vs Crisaborole: Topical PDE4 Inhibitors for Atopic Dermatitis in Pediatrics and Adults

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Dermatology in your inbox.

Related Drug Updates

IL-17 vs IL-23 vs TNF Inhibitors: 2025 Comparison for Plaque Psoriasis Treatment

FDA Approves Icotrokinra for Plaque Psoriasis: First Oral IL-23 Antagonist

FDA Approves Icotrokinra for Moderate to Severe Plaque Psoriasis: Oral IL-23 Antagonist for Patients 12 and Older

Verified HCP Portal